Cellid Co., Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Seoul Korea, Republic of (2006)

Organization Overview

First Clinical Trial
2016
NCT02866006
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cellid Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

adcld-cov19 (5 trials)

bnt162b2 (Comirnaty) (1 trial)

Drugs in Phase 1 Trials (2)

bvac-b (1 trial)

bvac-c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stomach Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 4